-
Mersana Therapeutics NASDAQ:MRSN Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.
Location: 840 Memorial Dr, Massachusetts, 02139-3789, US | Website: www.mersana.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
12.41%
Insider Ownership
1.51%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XMT-2056 (HER2 ADC) Details Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1 Data readout | |
Emiltatug Ledadotin (Emi-Le; XMT-1660) Details Ovarian cancer, Cancer, Breast cancer, Endometrial cancer | Phase 1 Data readout | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
XMT-1592 (NaPi2b antigen) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Failed Discontinued |